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Background. Chronic kidney disease is now recognized as an
independent risk factor for cardiovascular events. We sought
to determine if cardiovascular medications were utilized less in
patients with renal dysfunction following coronary artery by-
pass grafting (CABG) and if the association of decreased med-
ication use was independent of comorbid conditions. We also
examined associations between cardiovascular medication use
and mortality at 6 months.
Methods. Data from the National Veterans Adminstration
(VA) Continuous Improvement in Cardiac Surgery Program
were merged with the national VA pharmacy database. Pre-
scription rates within 6 months of discharge for CABG were
obtained for four classes of medicines: beta blockers, lipid-
lowering agents, antiplatelet agents, and angiotensin antag-
onists. Utilization of medications in patients with estimated
glomerular filtration rate (GFR) 60 to 90, 30 to 60, and <30
were compared with the reference group of GFR >90.
Results. In a retrospective analysis of 19,411 patients, the
frequency of nonprescription increased with declining GFR.
Decreased utilization for patients with GFR 30 to 60 and <30
remained highly significant after adjustment for age, race, hyper-
tension, diabetes, and prior myocardial infarction. In patients
with more advanced renal dysfunction (GFR <60), cardiovas-
cular medication use for all medication classes was associated
with survival at 6 months after adjusting for demographic and
1This is a U.S. Government work. There are no restrictions on its use.
Key words: cardiovascular disease, cardiac surgery, mortality.
Received for publication December 10, 2004
and in revised form February 28, 2005, and March 21, 2005
Accepted for publication March 30, 2005
C© 2005 by the International Society of Nephrology
clinical variables. Cumulative protection was seen with use of
medication from each additional class.
Conclusion. In a large VA population undergoing CABG,
renal disease is associated with highly significant decreases in
utilization of cardiovascular medications. Nonprescription of
medications was associated with adverse outcomes in those with
renal dysfunction.
Chronic kidney disease has recently been recognized
as an important independent risk factor for cardiovascu-
lar events and death from cardiovascular disease. The risk
of cardiovascular disease in chronic kidney disease is not
fully explained by the presence of multiple risks, includ-
ing hypertension, diabetes, older age, dyslipidemia, and a
high burden of left ventricular hypertrophy (LVH). Given
this information, the National Kidney Foundation has
recommended that patients with chronic kidney disease
be classified as a cardiovascular disease equivalent [1, 2].
Despite the growing frequency of chronic kidney disease
and adverse cardiac outcomes, recognition, prevention,
and treatment of cardiovascular disease in this patient
population are often poor. In many settings, chronic kid-
ney disease has been associated with decreased utiliza-
tion of key cardiovascular medications. In patients who
sustain myocardial infarction or have confirmed cardio-
vascular disease, patients receiving chronic dialysis and
those with chronic kidney disease have been shown to
have comparatively lower use of aspirin, angiotensin-
converting enzyme (ACE) inhibitors, beta blockers,
3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA)
reductase inhibitors, glycoprotein IIb/IIIa inhibitors, and
angiography [3–12]. Despite frequent exclusion from
randomized controlled trials of cardiovascular agents,
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patients with chronic kidney disease of various forms
have been shown to benefit from cardiovascular medica-
tions in randomized controlled trials. For example, stud-
ies of beta blockers have shown reductions in mortality in
end-stage renal disease (ESRD) patients with cardiomy-
opathy [13], studies of angiotensin receptor blockers have
lowered cardiovascular events in patients with type 2 di-
abetes and nephropathy [14], and studies of statins have
demonstrated reductions in cardiovascular events in pa-
tients receiving kidney transplants [15].
Following coronary artery bypass grafting (CABG),
prevention and treatment of underlying cardiovascu-
lar disease may have particular relevance. Specifically,
CABG may address the challenges posed by anatomic le-
sions of coronary artery disease, but does not remediate
the underlying disease process, atherosclerotic disease.
Here, secondary prevention with cardiovascular medi-
cations may prove beneficial [16, 17]. For lipid-lowering
agents, there are strong data supporting use after CABG
[18]. Aspirin, beta blockers, and angiotensin antagonists
are likely beneficial in improving graft patency, preven-
tion of atrial fibrillation, and in those with left ventricular
dysfunction [19–21]. ACE inhibitors are also beneficial
in unselected patients with atherosclerosis, with or with-
out low ejection fraction [22]. Mortality benefits for these
agents after CABG are suggested but have not yet been
rigorously proven [17].
Because preexisting kidney disease has been demon-
strated to be a predictor of adverse outcomes after CABG
[23], it seems logical to examine the chronic kidney dis-
ease population as a target for improving chronic kidney
disease–specific and overall outcomes in cardiac surgery.
Since the causes of underutilization in chronic kidney dis-
ease remain poorly understood [24], and there are no ex-
isting data on utilization of medications after CABG in
patients with chronic kidney disease, this area represents
a great knowledge deficit, especially in the United States
Veterans population. Our study aims were to determine if
chronic kidney disease is associated with lower cardiovas-
cular medication use after CABG in the Veterans Admin-
istration (VA) population and if factors explaining lower
prescription rates can be explained by demographic or
clinical factors. Given the lack of data for chronic kid-
ney disease patients in randomized controlled trials of
cardiovascular medications, we also hoped to determine
if cardiovascular medication use in patients with chronic
kidney disease is associated with improved 6-month sur-
vival after CABG.
METHODS
Study subjects and data collection
The VA Continuous Improvement in Cardiac Surgery
(CICSP) clinical data have been collected since 1987 on
all patients undergoing cardiac surgery in the VA hos-
pitals. Trained surgical clinical nurse reviewers at each
of the 43 cardiac surgical centers collect preoperative
risk factors, procedural details, and outcomes. The CI-
CSP database is reliable and accurate and has been em-
ployed successfully by other investigators [25]. From the
CICSP database, deidentified records for CABG proce-
dures performed between October 1, 1999 and March 31,
2003 were extracted for this retrospective analysis. For
the purposes of this study, valve procedures and repeat
operations were excluded. Because patients not surviv-
ing to discharge were ineligible to receive prescriptions,
patients with in-hospital death were also excluded. The
study population consisted of 19,411 subjects receiving
CABG and surviving to hospital discharge.
To obtain prescription fill rates, the CICSP data were
merged with the VA Pharmacy Benefits Management
Prescription Database (PBM) as part of the ongoing
quality improvement reporting initiatives within the VA
system. The PBM database contains information on all
pharmaceutical agents prescribed and filled in the VA
system. This comprehensive system is updated monthly.
For the analysis, four classes of drugs were selected for ex-
traction: antiplatelet agents, beta blockers, lipid-lowering
agents, and angiotensin antagonists. Antiplatelet agents
included aspirin, clopidogrel, dipyridamole, ticlopidine,
and other aspirin substitutes. Beta blockers included non-
selective and selective agents, as well as agents with in-
trinsic sympathomimetic activity. Lipid-lowering agents
included statins and nonstatin agents, and angiotensin
antagonists included ACE inhibitors and angiotensin re-
ceptor blockers.
Classification of patients into classes of renal functional
decline by estimated glomerular filtration rate (GFR)
was performed according to the formula of Cockroft and
Gault using the admission presurgery serum creatinine
value [26]. Race was unknown or missing for 3958 pa-
tients, preventing use of the newer Modification of Diet
in Renal Disease (MDRD) Study equation for estima-
tion of GFR [27]. For analysis of the association between
GFR and nonprescription, patients with GFR >90 were
used as the reference group. Clinical and demographic
variables were also extracted for baseline comparisons
and for multivariate analysis.
Study outcomes
The primary outcome of interest was nonprescription
within 6 months of discharge for each class of cardio-
vascular medication. Patients with GFR <30, GFR 30 to
60, and GFR 60 to 90 were compared with the reference
group of GFR >90. Nonprescription was defined as the
failure to fill any prescription for a class of medication
at any VA pharmacy within 6 months of discharge. Dis-
charge medications were included as prescriptions. Pre-
scriptions filled outside the VA system were not recorded.
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Table 1. Baseline characteristics of the Veterans Administration Continuous Improvement in Cardiac Surgery (VA CICSP) Study Population
(N = 19,411)
Glomerular filtration rate mL/min >90 60 to 90 30 to 60 <30 P valuea
Number % 8122 (41.8) 7236 (37.3) 3661 (18.9) 392 (2.0)
Age mean ± SD 58 ± 7.7 66 ± 8.2 72 ± 7.6 67 ± 10.3 <0.0001
Black race % 6.2 7.2 8.9 15.5 <0.0001
Hypertension % 82.8 85.6 88.7 92.7 <0.0001
Diabetes % 39.8 35.7 37.0 54.1 0.31
Prior myocardial infarction % 54.9 55.5 61.0 65.1 <0.0001
Left ventricular ejection fraction <40% % 11.4 12.2 16.0 19.4 <0.0001
Chronic obstructive pulmonary disease % 22.2 24.4 29.3 26.3 <0.0001
aChi-squared Mantel-Haenszel for categoric variables; analysis of variance (ANOVA) for continuous variables.
The 6-month time limit was chosen because some veter-
ans receive medications in 6-month increments, and pre-
operative medications would need to be refilled by that
time limit. The secondary outcome of interest was the
association between cardiovascular medication use and
all-cause mortality at 6 months in patients with advanced
renal decline (GFR <60). We also explored the incidence
of renal impairment in the study population and the as-
sociation between renal impairment and the risk of all-
cause mortality at 6 months. Mortality within 30 days was
captured by CICSP study nurses; other mortalities and
dates of death were captured by the Veterans Adminis-
tration “BIRLS” database which tracks the administra-
tion of death benefits.
Statistical analysis
Baseline variables were compared using the Cochran-
Mantel-Haenszel Chi-square for categoric variables and
analysis of variance (ANOVA) for continuous variables.
Hypertension, prior myocardial infarction, chronic ob-
structive pulmonary disease (COPD), and diabetes were
classified as binomial variables. Race was classified as
African American or non-African American.
Multivariate logistic regression was performed to de-
termine the effect of GFR on the rate of nonprescrip-
tion of antiplatelet agents, beta blockers, lipid-lowering
agents, and angiotensin antagonists. For beta blockers,
patients with COPD were excluded from the analysis.
For angiotensin antagonists, the analysis was repeated
using those patients with left ventricular ejection frac-
tion (LVEF) <40%, as this group has the most widely
recognized indication to receive angiotensin antagonists.
Multivariate analysis was adjusted for patient age, race,
hypertension, diabetes, prior myocardial infarction, and
each of the individual medication classes.
To determine if secondary prevention appeared bene-
ficial, we used logistic regression to analyze if medication
use from the above classes was associated with improved
survival at 6 months. This was performed in patients with
and without advanced renal impairment (GFR <60). Pa-
tients who died within 30 days of surgery were excluded,
as they would not have had an opportunity to fill any
outpatient prescriptions. We also analyzed the effects of
using multiple classes of cardiovascular medications on 6-
month mortality. The analysis of the effect of medication
use on 6-month mortality was adjusted for patient age,
race, hypertension, diabetes, baseline serum albumin, and
baseline serum creatinine. All analyses were performed
using SAS version 8.2 (SAS Institute, Cary, NC, USA).
As part of the VA Continuous Improvement in Cardiac
Surgery Program’s initiative to explore opportunities to
improve processes of care for CABG patients, this study
subanalysis was incorporated into the Colorado Multiple
Institutional Review Board (COMIRB) approval. As ap-
propriate for records received since April 2003, a Health
Insurance Portability and Accountability Act (HIPAA)
waiver of authorization was obtained.
RESULTS
Baseline characteristics of the study population and
distribution according to GFR are found in Table 1. In-
formation for analysis was available for 19,411 patients,
99% of whom were male. Renal functional impairment,
defined by a GFR <90, was present in the majority of the
study population (58.2%). Advanced renal impairment,
defined as GFR <60, was found in 20.9% of the popula-
tion. Hypertension was present in 85% of patients, and
prior myocardial infarction had occurred in 54.5%. Dia-
betes and COPD were also common, occurring in 38%
and 24.5%, respectively. In addition, 12.7% had an ejec-
tion fraction (EF) less than 40%, and 7.2% were classi-
fied as African American. While most variables showed
statistically significant differences among GFR groups at
baseline due to the large numbers of patients, clinically
significant differences existed. Patients with renal disease
tended to be older, were more likely to be black, and had
higher incidences of hypertension, prior myocardial in-
farction, EF <40%, and COPD. Over 50% of patients
with GFR <30 had a diagnosis of diabetes.
The frequencies of study endpoints (nonprescription,
6-month mortality) stratified by GFR are found in
Table 2. For each class of agents, a highly significant, step-
wise decrease in the rate of utilization was seen as kidney
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Table 2. Frequency of study end points: Nonprescription and
mortality by glomrular filtration rate (GFR) group
GFR mL/min All >90 60 to 90 30 to 60 <30 P valuea
Antiplatelet 18.0 16.2 17.3 22.5 26.0 <0.0001
agents %
Lipid-lowering 20.7 16.2 20.6 29.1 39.0 <0.0001
agents %
Beta blockersa % 12.3 8.4 11.4 14.7 20.8 <0.0001
Angiotensin 39.0 38.3 38.3 41.3 46.9 <0.0002
antagonists %
6-month mortality % 4.7 2.7 4.2 9.0 13.5 <0.0001
aPatients with chronic obstructive pulmonary disease excluded for beta
blockers.
function declined. For angiotensin antagonists, these dif-
ferences were not seen in the GFR 60 to 90 vs. the refer-
ence group. However, for all other GFR groups and each
of the four medication classes, there were statistically sig-
nificant decreases in utilization with each advancing stage
of kidney disease. We also verified previous findings of
the effect of presurgery GFR on outcomes. GFR power-
fully predicted mortality at 6 months (P < 0.0001), with
13.5% of patients in the GFR <30 group experiencing
mortality after surviving to discharge. This rate declined
to 9.0%, 4.1%, and 2.7% in the GFR 30 to 60, 60 to 90,
and >90 groups, respectively. The results for Tables 3 and
4 will be discussed below for each class of medication. In
Table 5, we demonstrate the cumulative effect of receiv-
ing cardiovascular medications on the odds of mortality at
6 months. Specifically, the odds of mortality at 6 months
decrease dramatically with prescription of medications
from each additional class. This apparent benefit is seen
in patients with and without GFR <60.
Antiplatelet agents
A total of 18% of patients in the CICSP study did not
receive any antiplatelet agent from a VA pharmacy within
6 months of discharge. These gross rates are likely influ-
enced by over-the-counter purchase of aspirin outside VA
sources. However, a strong influence of GFR was seen
on the odds of nonprescription. The unadjusted odds of
nonprescription were significantly higher for each GFR
group when compared to the reference group. After ad-
justing for patient age, hypertension, race, prior myocar-
dial infarction, diabetes, and use of other cardiovascular
medications, the odds of nonprescription was not signif-
icantly different among GFR groups. We found that of
all the factors included in the analysis, adjustment for
other medications erased the univariate differences in
prescription among GFR groups. Thus, it appears that
prescription of other cardiovascular agents strongly af-
fects prescription of antiplatelet agents within various
GFR categories. In those patients with GFR <60 (Table
4), nonprescription of antiplatelet agents was associated
with a highly significant increase in the odds of death at 6-
months. Adjusting for age, hypertension, diabetes, serum
creatinine, serum albumin, and race did not change the
highly significant nature of the association between non-
prescription and death (OR 1.90, P = 0.004).
Beta blockers
After excluding 4746 patients with COPD, beta block-
ers were not prescribed in 12.3% of patients. Again, the
presence of renal impairment was highly associated with
decreased utilization. Only 8.4% of those with GFR >90
did not receive beta blockers. This rate rose to 11.4%,
15%, and 21% in those with GFR 60 to 90, 30 to 60,
and <30. The adjusted odds of nonprescription was sta-
tistically significant for the GFR 60 to 90 and GFR <30
groups compared with the reference group. There was a
strong association seen between nonprescription of beta
blockers and increased odds of mortality at 6 months.
This association remained highly significant (OR 3.04,
P < 0.0001) even after adjusting for age, hypertension,
diabetes, serum creatinine, serum albumin, race, and use
of other cardiovascular medications.
Lipid-lowering agents
Lipid-lowering agents were not prescribed in 20.7% of
the study population. In those with GFR >90, only 16%
did not receive any lipid-lowering agent. With each ad-
vancing stage of renal impairment, rates of nonprescrip-
tion rose to 21%, 29%, and 39%. The unadjusted odds
of nonprescription was highly significant in each of the
GFR groups, while the adjusted odds of nonprescription
were statistically significant in the GFR <30 and GFR
30 to 60 groups; these differences increased in magnitude
as kidney function declined (Table 3). Nonprescription
of lipid-lowering agents was associated with a highly sig-
nificant increase in mortality at 6 months in the adjusted
analyses in those with advanced renal impairment (GFR
<60). The adjustment for serum albumin makes it un-
likely that lipid-lowering agents were not prescribed due
to malnutrition in patients with kidney disease.
Angiotensin antagonists
Angiotensin antagonists (ACE inhibitors and an-
giotensin receptor blockers) were not prescribed in 39%
of the study population, and were not prescribed in 27.8%
of the 2472 patients with LVEF <40%. Again, the gross
rates of nonprescription increased as kidney function de-
clined, except for those with GFR 60 to 90. The unad-
justed and adjusted odds of nonprescription were highly
significant in those with GFR 30 to 60 and <30. This re-
lationship was even stronger for the patients with LVEF
<40% (Table 3). For example, those with GFR <30 and
EF<40% had an adjusted odds of nonprescription of
2.83 (P < 0.001). Again, failure to receive angiotensin
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Table 3. Associations between glomerular filtration rate (GFR) category and odds of nonprescription
GFR 60 to 90 GFR 30 to 60 GFR <30
Antiplatelet agent
ORa (95% CI) 0.88 (0.80–0.98) 0.97 (0.85–1.10) 1.07 (0.82–1.39)
P value 0.01 0.62 0.62
Lipid-lowering agent
ORa (95% CI) 1.04 (0.95–1.15) 1.28 (1.13–1.44) 2.08 (1.63–2.65)
P value 0.41 <0.0001 <0.0001
Beta blockers
ORa (95% CI) 1.20 (1.04–1.39) 1.16 (0.96–1.40) 1.49 (1.05–2.12)
P value 0.01 0.11 0.02
Angiotensin antagonists
ORa (95% CI) 1.01 (0.94–1.09) 1.15 (1.04–1.27) 1.50 (1.20–1.88)
P value 0.76 0.008 <0.001
Angiotensin antagonist, ejection fraction <40%
ORa (95% CI) 1.08 (0.84–1.39) 1.62 (1.19–2.19) 2.83 (1.64–4.91)
P value 0.56 0.002 <0.001
aVariables included age, diabetes, hypertension, race, prior myocardial infarction, and each cardiovascular medication class; GFR >90 is reference.
Table 4. Relationship of medication nonprescription to 6-month
mortality in patients with and without advanced renal disease
[glomerular filtration rate (GFR) <60]
GFR <60 GFR >60
Failure to receive (N = 3260) (N = 12,396)
Antiplatelet agents
ORa (95% CI) 1.90 (1.23–2.94) 2.00 (1.37–2.91)
P value 0.004 <0.001
Lipid-lowering agents
ORa (95% CI) 3.69 (2.36–5.77) 3.44 (2.36–5.01)
P value <0.0001 <0.0001
Beta blockers
ORa(95% CI) 3.04 (1.94–4.76) 3.43 (2.34–5.03)
P value <0.0001 <0.0001
Angiotensin antagonists
ORa (95% CI) 1.77 (1.14–2.76) 2.02 (1.40–2.92)
P value 0.01 <0.001
aVariables included age, race hypertension, diabetes, creatinine, serum
albumin, and each cardiovascular medication class. Patients who died within 30
days of surgery were excluded.
antagonists after discharge was associated with substan-
tial increase in the odds of 6-month mortality, even
after adjustment for age, race, hypertension, diabetes,
serum creatinine, serum albumin, and other cardiovas-
cular medications.
DISCUSSION
Our study provides important new information link-
ing the presence of renal impairment with decreased
utilization of important cardiovascular medications af-
ter CABG. Although other unmeasured factors (such
as medication use outside of the VA health care sys-
tem) may have influenced the observed medication fill
rates, the graded relationship between nonprescription
of each agent and advancing renal decline provides
enhanced support that this is a true association. Fur-
thermore, we also found that these associations between
medication underutilization and GFR were retained af-
ter adjustment for demographic and clinical factors such
Table 5. Cumulative protective effect of cardiovascular medications
on 6-month mortality in patients with and without advanced renal
disease [glomerular filtration rate (GFR) <60]
GFR <60 GFR >60
Three medicationsa 1398 5807
ORa (95% CI) 2.48 (1.24–4.94) 1.20 (0.72–2.00)
P value 0.01 0.49
Two medicationsa 566 1852
ORa (95% CI) 6.54 (3.26–13.15) 3.88 (2.32–6.49)
P value <0.0001 <0.0001
One medicationa 150 379
ORa (95% CI) 15.29 (7.01–33.35) 6.56 (3.24–13.30)
P value <0.0001 <0.0001
Zero medicationsa 395 569
ORa (95% CI) 39.00 (20.79–73.18) 36.19 (23.38–56.03)
P value <0.0001 <0.0001
aVariables included age, race, hypertension, diabetes, creatinine, serum
albumin, HTN. Reference was patients who received cardiovascular medications
from all four classes.
as age, race, hypertension, diabetes, and prior myocar-
dial infarction. Given the completeness and quality of the
CICSP national quality improvement database, the rele-
vance of underutilization in the setting of chronic kidney
disease is dramatically underscored by our data defining
the incidence and outcomes of renal impairment in the
VA CABG population. Specifically, we have shown that
among patients undergoing CABG, the majority (58%)
of patients had some degree of renal functional impair-
ment, and that fully 21% had GFR <60. While others
have shown that events increase in patients with higher
values of serum creatinine [23], our study provides con-
clusive information that as kidney function declines, there
is a highly significant increase in the risk of mortality at
6 months, even after excluding those who died prior to
discharge.
This study also suggests that as in patients with nor-
mal or slightly reduced GFR, patients with GFR <60
benefit from receiving cardiovascular medications after
CABG, an association which has not been previously
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demonstrated. The greater odds of death at 6 months in
patients with GFR <60 who failed to receive each class of
medication and the dramatically increased survival when
patients received medications from each additional class
underscored this point. While associations between med-
ication use and decreased risk of death were observa-
tional in nature, the strong relationship and persistence
after multivariate adjustment argue that chronic kidney
disease patients are probably helped, and are likely not
harmed, by cardiovascular medications.
In addition to documenting the presence of underuti-
lization of cardiovascular medication in the chronic kid-
ney disease population, our data also make a compelling
argument that disparities in utilization should be elim-
inated. While reasons may exist for decreased utiliza-
tion, such as bleeding complications for aspirin, hyper-
kalemia for ACE-inhibitors, and myopathy for statins,
the high risk of cardiovascular events in the chronic kid-
ney disease population should render these side effects
less important. For example, the 9.0% and 13.5% risk
of death at 6 months in patients with GFR 30 to 60 and
<30 in our study probably outweighs the 1.9% risk of
serious hyperkalemia with angiotensin receptor blockers
seen in large trials of patients with chronic kidney disease
[28], although extensive safety data does not exist for pa-
tients with GFR <30 due to their exclusion from clini-
cal trials. Similarly, occasional myopathy and rare (<1%)
clinically important creatinine kinase elevations are not
an adequate explanation for nonprescription of statins,
given our data on apparent protection in all patients and
prospective data in the general CABG population [18,
29]. While we remain unable to explain the apparent
therapeutic disconnect between the extremely high-risk
chronic kidney disease population and routine use of sec-
ondary prevention, we hope that this study will highlight
and begin to reverse the unfortunate trend of undermed-
icating and undertreating chronic kidney disease patients
with cardiovascular agents.
The strengths of this study are the large number of pa-
tients, the complete nature of the dataset [25], and the
ability to link demographic and clinical factors with com-
prehensive pharmacy information and patient outcomes.
In the United States, this sort of information is not fre-
quently available except in large managed care organi-
zations [30]. Because the study captured all patients re-
ceiving CABG in the VA system, it has the potential abil-
ity to raise similar questions that may be faced by other
national health insurance programs (e.g., Medicare) or
international health programs (e.g., Canadian or other
national health care system). Other strengths include the
ability to adjust for multiple factors that may affect pre-
scription rates and outcomes.
Despite the comprehensive nature of the dataset, there
are limitations inherent in any observational or retro-
spective study design. Risk adjustment may not equiva-
lently account for differences in patients with advancing
degrees of chronic kidney disease; thus, our study does
not prove that renal disease is the causative factor in
decreased utilization of cardiovascular medications, nor
does it prove that decreased utilization is the causative
factor behind decreased survival in those who fail to re-
ceive cardiovascular medications. However, our primary
focus was not to prove causation, but to identify gaps in
clinical care that could serve as future quality improve-
ment targets. The PBM data on prescription information
is limited by the extent that patients may fill their med-
ications outside the VA system. It is unknown to what
degree veterans utilized prescription drug benefits
through another insurance system (e.g., their state-based
Medicaid program provided pharmacy coverage). Also,
if aspirin, niacin, or other low-cost medication can be
obtained over the counter at a lower cost, patients may
purchase medications outside the VA. It is likely that vet-
eran use of external pharmacy services affects aggregate
rates of nonprescription, however, but fails to explain
large differences in patients with renal impairment or im-
proved outcomes in those who receive medications. We
also did not assess regional or physician-specific varia-
tion in this study, which may be a topic of further investi-
gation. Compliance (patients who received prescriptions
but did not fill them) was not measured either, which lim-
its our conclusions. Additionally, unmeasured patient risk
factors (e.g., clinical contraindications to cardiovascular
medications) are not measured in this study. Finally, any
VA study is limited to the extent that the veterans are
not generally representative of the United States pop-
ulation. However, our group has previously published
data that showed similar utilization of cardiovascular
medications in the post-CABG cohort when compared
with other populations [31]. Thus, we believe our results
are likely to correspond to other populations receiving
CABG.
CONCLUSION
Renal impairment existed to some degree in the ma-
jority of the VA population undergoing CABG and was
strongly associated with decreased use of key cardiovas-
cular medications. These differences in prescription were
not fully explained by demographic or clinical factors.
Furthermore, our data suggest that patients with renal
disease likely derive substantial benefit from cardiovas-
cular medications. Since the presence of advancing renal
functional decline was a powerful predictor of adverse
outcomes, quality and prevention efforts in chronic kid-
ney disease should be refocused on secondary prevention
with cardiovascular medications after CABG and in other
cardiovascular disease settings.
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